


CREON 36K

QUICK REFERENCE DOSING SUMMARY

GETTING STARTED WITH CREON 36K

36K capsules can be an appropriate strength for many patients¹



Usually, half the prescribed CREON dose for an individualized full meal should be taken with each snack.¹

This chart is intended to be a guide. CREON capsules represent nearest capsule count within recommended dosing range.

Patients weighing <110 lb may require a lower lipase unit starting dose. Patients weighing >315 lb may require a higher lipase unit starting dose.

The CREON dosage you prescribe should be initiated at the lowest recommended dose based on the patient's weight and individualized based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.¹ Dosing of pancreatic enzymes is based on the guidelines established by the Cystic Fibrosis Foundation.¹

CREON 36,000 may not be appropriate for all patients. CREON is also available in 3,000, 6,000, 12,000, and 24,000 lipase unit capsules.¹

SCHEDULE AN EARLY FOLLOW-UP TO ASSESS THE NEED FOR TITRATION

CREON dosage should be individualized and adjusted based on¹:

- ✓ Clinical symptoms
- ✓ Degree of steatorrhea present
- ✓ Fat content of the diet

When titrating, prescribe a dose within the recommended range based on patient weight^{1*}

Patient weight	MINIMUM per-meal dose	MAXIMUM per-meal dose
110 lb 49.9 kg	36,000 lipase units	108,000 lipase units
130 lb 59.0 kg	36,000 lipase units	144,000 lipase units
160 lb 72.6 kg	72,000 lipase units	180,000 lipase units
200 lb 90.7 kg	72,000 lipase units	216,000 lipase units
230 lb 104.3 kg	72,000 lipase units	252,000 lipase units

*Based on guidelines established by the Cystic Fibrosis Foundation (CFF).

This chart is intended to be a guide. CREON capsules represent nearest capsule count within recommended dosing range.

Capsules shown are not actual size and do not represent exact color shade. For illustrative purposes only.

CREON 36,000 may not be appropriate for all patients. CREON is also available in 3,000, 6,000, 12,000, and 24,000 lipase unit capsules.¹

INDICATIONS¹

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

SAFETY CONSIDERATIONS

- Fibrosing colonopathy has been reported in patients with cystic fibrosis taking high dose pancreatic enzyme replacement therapy.
- Use caution when prescribing CREON to patients with gout, renal impairment, or hyperuricemia, and in patients with pork allergies.
- There is a theoretical risk of viral transmission with pancreatic enzyme products including CREON.
- CREON should always be taken with food. CREON should not be crushed or chewed.


Please see additional Important Safety Information on next page.

Please click here for Full Prescribing Information, including Medication Guide.

abbvie

CREON[®]
(pancrelipase)
Delayed-Release Capsules

PRESCRIBE CREON FOR BOTH MEALS AND SNACKS¹



REMINDER: When writing prescriptions (on paper or e-prescribing systems), make sure to specify the number of capsules that should be taken **per meal and per snack**¹

CREON 36,000

Duration	Quantity
30	240

Notes

2 caps po during each meal
1 caps po during each snack
Note: Take during every meal and snack

SEND

Sample scripts for a patient who weighs 160 lb.

IMPORTANT SAFETY INFORMATION

- Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
- To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
- Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
- There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
- Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
- Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
- Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
- CREON is not interchangeable with any other pancrelipase product.

Please click here for [Full Prescribing Information, including Medication Guide.](#)

Reference:

1. CREON [package insert]. North Chicago, IL: AbbVie Inc.